Cognitive Biases Modification Treatment for Social Anxiety

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01503151

Acronym

CBMSP

Enrollment

Registered

2012-01-02

Start date

2012-01-31

Completion date

2014-03-31

Last updated

2014-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Social Phobia

Keywords

attention bias modification treatment, interpretive bias modification, cognitive bias modification, attention training, social anxiety

Brief summary

Adults with Social Phobia will be randomly assigned to either an attention bias modification treatment, interpretation bias modification treatment, both, or a placebo control condition not designed to change cognitive bias patterns. Outcome measures will be social anxiety symptoms and severity as measured by gold standard questionnaires as well as diagnosis of social phobia disorder and symptom counts derived from structured clinical interviews based on DSM-IV criteria. The investigators expect to find significant reduction in social anxiety symptoms in the Treatment groups relative to the placebo control group. The investigators want to find out the relative efficacy of attention and interpretation oriented treatments and the combination of the two.

Interventions

BEHAVIORALAttention Bias Modification Treatment (ABMT)

Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.

BEHAVIORALInterpretation Bias Modification (IBM)

Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias.

BEHAVIORALControl Condition

Attention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns.

BEHAVIORALAttention and Interpretive biases modification (CBM)

Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias.

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

People suffering from social anxiety

Exclusion criteria

Pharmacological or Psychological treatment

Design outcomes

Primary

Measure	Time frame	Description
Social Anxiety Scale (LSAS) - diagnostic interview	Expected time frame of 6 weeks per participant. Participants will be assessed before and after the administration of the training/control protocols	LSAS is a 24-items clinician-administered scale developed for the assessment of fear and avoidance associated with social. The LSAS assesses a wide range of both social interaction and performance/observation situations, which are rated for degree of fear/anxiety and frequency of avoidance.

Secondary

Measure	Time frame	Description
The Mini International Neuropsychiatric Interview (MINI).	expected time frame of 6 weeks per participant. Participants will be assessed before and after the administration of the training/control protocols	The Mini International Neuropsychiatric Interview (MINI) is a short diagnostic structured interview (DSI) developed to explore 17 disorders according to Diagnostic and Statistical Manual diagnostic criteria (DSM)

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026